A cell-permeable, reversible, and ATP-competitive Ca²⁺ antagonist with anti-vasospastic properties. Inhibits protein kinase A (K_i = 1.6 µM), protein kinase G (K_i = 1.6 µM), and myosin light chain kinase (K_i = 3.6 µM). Also reported to potently inhibit Rho-associated kinase (ROCK; IC₅₀ = 10.7 µM). Prevents apoptosis and enhances the survival and cloning efficiency of dissociated hES cells without affecting their pluripotency.

Cell permeable: yes

Primary Target
PKA

Product competes with ATP.

Reversible: yes

Target IC₅₀: 10.7 µM inhibiting Rho-associated kinase (ROCK)

Target K_i: .6 µM, 1.6 µM, 36 µM, inhibiting protein kinase A, protein kinase G, myosin light chain kinase, respectively

Toxicity: Harmful (C)

Following reconstitution, refrigerate (4°C). Aqueous stock solutions are stable for up to 6 months at 4°C.

Watanabe, K., et al. 2007. Nature Biotech.25, 681.
Swärd, K., et al. 2000. J. Physiol.522, 33.
Takizawa, S., et al. 1993. Eur. J. Pharmacol. 250, 431.
Seto, M., et al. 1991. Eur. J. Pharmacol.195, 267.
Shirotani, M., et al. 1991. J. Pharmacol. Exp. Ther.259, 738.
Asano, T., et al. 1990. Eur. J. Pharmacol.190, 365.
Sasaki, Y., and Sasaki, Y. 1990. Biochem. Biophys. Res. Commun.171, 1182.
Asano, T., et al. 1989. Br. J. Pharmacol. 98,1091.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany